History
& Key Facts
2026
ANTABIO announces a collaboration with GARDP to accelerate early-stage antibiotic discovery. This partnership focuses on advancing hit-to-lead projects targeting carbapenem-resistant Gram-negative bacteria, with the aim of developing novel treatments for drug-resistant infections.
2023
ANTABIO Raises €25 million in Series B Financing. Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will be used to support the clinical development of MEM-ANT3310.
2023
Start of the Phase 1 clinical trial of MEM-ANT3310, Antabio’s lead program being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE).
2022
Launch of ARPEGE, a multidisciplinary AMR consortium led by Antabio with €5.5m public funding to support the development of MEM-ANT3310 towards clinical studies.
2020
FDA grants Qualified Infectious Disease Product (QIDP) designation to MEM-ANT3310 for major hospital indications including nosocomial pneumonia.
2019
CARB-X renews support for ANT3273 further to the completion of the first stage milestones. $4.4 Million awarded up to the completion of non-GLP preclinical studies.
2018
Antabio completes €12.5m Series A.
2017
CARB-X awards Antabio ANT3273 with funding of up to $2.8 million with options for up to $8.9 million upon achievement of milestones.
2015
The Wellcome Trust awards Antabio €4.0 million Seeding Drug Discovery Award for the development of a small molecule inhibitor of Pseudomonoas aeruginosa biofilms (ANT3273).
2013
The Wellcome Trust awards Antabio €4.7 million Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of life-threatening infections caused by multi-drug resistant Gram-negative bacteria (MEM-ANT2681).